Four Leading Oncologists Discuss the Practicalities of Whole Genome Sequencing
In the first of a two-part video series, Dr Angela George, Professor Noel Clarke, Dr Nirupa Murugaesu, and Dr Richard Simcock reflect on the advantages and disadvantages of whole genome sequencing for patients and oncologists, and look at its impact on oncology survival rates.
They examine issues around data generation and management, cost, whether targets in the NHS Long Term Plan1 are achievable, and managing the backlog of care in the NHS.
Dr Angela George
Consultant Medical Oncologist, Consultant in OncoGenetics, and Clinical Director of Genomics, Royal Marsden Hospital, London
Professor Noel Clarke
Consultant Urological Surgeon, The Christie NHS Foundation Trust, Manchester; Professor of Urological Oncology, University of Manchester
Dr Nirupa Murugaesu
Consultant in Medical Oncology, St George's Hospital; Cancer Genomics Medical Lead for the London South Genomics Laboratory Hub
Dr Richard Simcock
Consultant Clinical Oncologist, University Hospitals Sussex, Brighton; National Clinical Adviser for Macmillan Cancer Support